- Home
- AMPL vs EYPT Comparison
AMPL vs EYPT Comparison
Compare AMPL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMPL | EYPT |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AMPL | EYPT |
|---|---|---|
| Price | $10.71 | $12.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $13.42 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 1.9M | 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.84 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $343,214,000.00 | $7,539,000.00 |
| Revenue This Year | $17.43 | N/A |
| Revenue Next Year | $14.16 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.68 | N/A |
| 52 Week Low | $5.51 | $9.65 |
| 52 Week High | $12.80 | $19.11 |
Technical Indicators
Market Signals| Indicator | AMPL | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue through selling subscriptions to the platform. The company derives a majority of its revenue from the United States, and also has its presence in Internationally.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.